Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zileuton and Dasatinib in Chronic Myelogenous Leukemia
NCT02047149Phase 1Terminated
- Sponsor
- University of Massachusetts
- Start
- Jan 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zileuton extended release in chronic myelogenous leukemia (CML), sponsored by University of Massachusetts. Primary endpoint: Maximal Tolerated Dose at 36 months. Started Jan 2014; status: terminated.
02
Drugs
zileuton extended release
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT02047149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047149.